Order to Sell Generic 'Ditaxel' to a Third Party Within Six Months
as a Condition for Acquiring Marketing Rights of Original Anticancer Drug 'Taxotere'

Boryung, the second-largest player in the domestic docetaxel-based anticancer drug market, has faced a strong regulatory block from the Korea Fair Trade Commission (KFTC) as it attempted to acquire the marketing rights for the leading original drug. The KFTC conditionally approved the acquisition, but only on the grounds that Boryung must divest its existing generic drug (generic) business assets. This measure aims to prevent price increases and consumer harm resulting from a monopoly.

KFTC Orders Corrective Action Against Boryung Over Monopoly Concerns... Original Anticancer Drug Acquisition Conditional on Generic Divestiture View original image

On June 4, the KFTC announced that, after reviewing the proposed business combination in which Boryung would acquire the marketing rights for 'Taxotere,' the original docetaxel-based breast cancer treatment from French multinational pharmaceutical company Sanofi, it determined there was substantial concern over significant restriction of market competition. As a corrective measure, the KFTC ordered Boryung to sell all business-related assets of its own generic, 'Ditaxel,' to a third party.


This merger is a horizontal combination, with Boryung, a domestic supplier of generics, acquiring the global marketing rights of the original drug containing the same active ingredient. Based on 2024 sales figures, Sanofi (Taxotere) holds the top position in the domestic docetaxel anticancer drug market with a 64.7% share, while Boryung (Ditaxel) follows with 13.8%. The remaining six competitors each hold only a minimal share. If the two companies merge, their combined market share would reach a dominant 78.5%, creating an overwhelming monopoly.


The KFTC imposed such a strong structural remedy due to concerns over the elimination of the second-ranked product, which has served as the closest competitor to the market leader. According to the Pharmaceutical Affairs Act, a single pharmaceutical company cannot hold multiple manufacturing approvals for products with the same ingredient and formulation. Therefore, if Boryung proceeds to directly manufacture and sell Taxotere, it would be obliged to relinquish Ditaxel’s approval.


If this occurs, not only would a meaningful competitor disappear from the market, but Boryung’s 'alcohol-free product (Ditaxel),' uniquely developed in Korea in 2023 to reduce patients’ risk of alcohol dependence, would also vanish from the market. The KFTC explained that an economic analysis projected a 4.6% to 9.3% price increase and a maximum KRW 7.78 billion decline in consumer welfare following the merger.


Accordingly, the KFTC has ordered Boryung to sell all tangible and intangible assets related to Ditaxel—including product approval rights, marketing materials, and technical data—within six months (with a possible six-month extension) to a third-party pharmaceutical company that does not currently sell docetaxel-based anticancer drugs. Until the divestiture is complete, Boryung is prohibited from suspending the production or supply of Ditaxel, or inducing customers to switch to Taxotere. Even after the sale, Boryung is urged to provide finished product supply and technical support for a certain period if requested by the buyer.



A KFTC official stated, "This action is significant in that it preemptively blocked the negative effects of a monopoly in the anticancer drug market, which is directly linked to the lives and health of the public. As a result of this measure, the price and quality competition mechanism between original and generic drugs will be maintained, and the stable supply of essential medicines through the direct domestic manufacture of Taxotere will also be secured."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing